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a b s t r a c t
Immunosuppression is an important treatment modality in transplantation and human diseases that
are associated with aberrant T cell activation. There are considerable differences regarding the cellular
processes targeted by the immunosuppressive drugs that are in clinical use. Drugs like azathioprine
(Aza) mainly act by halting proliferation of fast dividing cells, whereas others like cyclosporine A (CsA)
speciﬁcally target signaling pathways in T cells. Since the outcome of T cell responses critically depends
on the quality and strength of costimulatory signals, this study has addressed the interplay between
costimulation and the immunosuppressive agents CsA and Aza during the in vitro activation of human T
cells. We used an experimental system that allows analyzing T cells activated in the presence of selected
costimulatory ligands to studyT cells stimulated via CD28, CD2, LFA-1, ICOSor 4-1BB. Themean inhibitoryzathioprine concentrations (IC50) for Aza and CsA were determined for the proliferation of T cells receiving different
costimulatory signals as well as for T cells activated in the absence of costimulation. CD28 signals but not
costimulation via CD2, 4-1BB, ICOS or LFA-1 greatly increased the IC50 for CsA. By contrast, the inhibitory
effects of Aza were not inﬂuenced by T cell costimulatory signals. Our results might have implications
for combining standard immunosuppressive drugs with CTLA-4Ig fusion proteins, which act by blocking
CD28 costimulation.
         
. Introduction
T cells have important roles in allograft rejection, graft versus
ost diseases and autoimmune pathologies. In most cases the clin-
cal management of these conditions requires the extensive use
f immunosuppressive agents to control aberrant T cell responses.
uch drugs limit and down-modulate T cell activation by targeting
ifferent cellular processes. Drugs like azathioprine (Aza) mainly
ct by halting proliferation of fast dividing cells, whereas others
ike Cyclosporine A (CsA) more speciﬁcally target T cells by inter-
ering with signaling pathways in these cells. Since many different
ignals can contribute to T cell activation processes, the interplay
etween such signals and immunosuppressive agents might have
ifferential effects on the outcome of T cell responses. Especially
ostimulatory signals generated by interaction of antigen pre-
enting cells (APC)-expressed ligands with their T cell-expressed
Abbreviations: Aza, azathioprine; CsA, Cyclosporine A; APC, antigen presenting
ells; IC50, mean inhibitory concentration.
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receptors have a crucial role in the efﬁcient activation of T cells
that recognize antigen. The interaction of CD80/CD86 with CD28 is
generally regarded as the primary T cell costimulatory pathway [1].
However, therearemanyalternative costimulatory ligand-receptor
pairs that potently enhance the proliferation, differentiation and
cytokine production of T cells that recognize antigens [2–4]. Among
these the CD58 – CD2, 4-1BBL – 4-1BB, ICOS-L – ICOS and CD54 –
LFA-1 (CD11a/CD18) pathways are well documented to generate
strong and consistent costimulatory effects in human T cells [2,5].
Costimulatory receptors belong to different molecule-families and
consequently they can induce signaling events that are distinct
from the pathways induced by CD28 ligation. Previous studies have
shownthatengagementof theCD28costimulatorypathwaygreatly
reduces the sensitivity of T cells to the immunosuppressive effect of
CsA [6,7]. By contrast, it is not knownwhether triggeringalternative
costimulatory receptors has similar effects. Furthermore, currently
there is limited knowledge how different costimulatory signals
affect the immunosuppressive effects of other drugs in clinical use.
We have previously developed a cellular system termed T cell
stimulator cells that allows analyzing the effect of different cos-
timulatory signals on human T cells [5,8,9]. This system is based
on cell lines engineered to express membrane-bound anti-human-
CD3 antibody-fragments that trigger the TCR-complex on human
J. Leitner et al. / Immunology L
Fig. 1. Characterisation of the T cell stimulator cells used in this study. Character-
isation of T cell stimulator cells expressing anti-CD3high in conjunction with CD80,
CD58, 4-1BBL, ICOS-L, CD54 or no costimulatory molecule (control) by FACS. Left
panel: expression of mb-anti-CD3 antibodies on stimulator cells; open histograms:
parental Bw cells. Right panel: T cell stimulator cells expressing CD80, CD58, 4-1BBL,
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dCOS-L or CD54 were probed with antibodies speciﬁc for these molecules (ﬁlled his-
ograms); open histograms: reactivity of the indicated antibodies with parental Bw
ells.
 cells upon co-culture. By expressing high levels of human cos-
imulatory ligands of interest on the T cell stimulator cells it is
ossible to analyze and compare human T cells that receive distinct
ostimulatory signals. In this study we used T cell stimulator lines
xpressing CD80, CD58, 4-1BBL, ICOS-L. CD54 and T cell stimulator
ines expressing anti-CD3 antibody-fragments but no costimula-
ory molecules to activate T cells puriﬁed from healthy individuals.
sing this system we determined the mean inhibitory concentra-
ions (IC50) for CsA and Aza for the proliferation of human T cells
eceiving different costimulatory signals.
. Material and methods.1. Antibodies, cell culture and FACS staining
293T cells and the mouse thymoma cell line Bw5147 (short
esignation within this work Bw) were cultured as describedetters 140 (2011) 74– 80 75
[9].  The ethical review board of the General Hospital and the
Medical University of Vienna approved the human studies per-
formed within this work and informed consent was obtained
from the donors. PBMC were isolated from heparinised whole
blood of healthy volunteer donors by standard density cen-
trifugation with Ficoll-Paque (Amersham Bioscience, Roosendaal,
Netherlands). Untouched human T cells were obtained through
depletion of CD11b, CD14, CD16, CD19, CD33 and MHC-class
II bearing cells with the respective mAbs by MACS (Miltenyi
Biotech, Bergisch Gladbach, Germany). Untouched CD8+ and
CD4+ T cells were isolated from human T cells using MACS
in conjunction with antibodies to CD8 or CD4. The mAbs to
CD4 (VIT4), CD8 (VIT8), CD11b (VIM12), CD14 (VIM13), CD33
(4D3), MHC-class II (1/47), CD80 (7-480), CD58 (1-456) and
CD54 (5-216) were produced at our Institute. The mAb  to
CD14 (MEM-18) was purchased from An der Grub (Kaumberg,
Austria), CD19 mAb  (BU12) from Ancell (Bayport, MN), 4-1BBL
from Biolegend (San Diego, CA) and ICOS-L (2D3/B7H2) from
BD Pharmingen (Palo Alto, CA). FACS analysis was performed as
described previously [10]. Brieﬂy, binding of primary antibodies
was  detected with PE-conjugated goat-anti-mouse IgG-Fc spe-
ciﬁc Abs (Jackson ImmunoResearch, West Grove, PA). Expression
of membrane-bound anti-CD3 antibody fragment was  detected
via APC-conjugated goat-anti-mouse IgG (H + L) Abs, which react
with the variable regions of murine antibodies (Jackson ImmunoRe-
search). Fluorescence intensity is shown on a standard logarithmic
scale.
2.2. T cell activation in the presence of different costimulatory
molecules
Human T cells (1 × 105/well) were co-cultured for 72 h with
irradiated (6000 rad) T cell stimulator cell lines (2 × 104/well)
expressing high levels of membrane-bound anti-CD3 antibody-
fragments and one of the following costimulatory ligands: CD80,
CD58, 4-1BBL, ICOS-L, CD54 or control T cell stimulator cells
expressing anti-CD3 but no human costimulatory molecules as
described [5].  In some experiments 5 × 104/well T cell stim-
ulator cells were used. Cyclosporine A (CsA; Sandimmun®,
Novartis Pharma, Basel, Swiss) and azathioprine (Aza; Imurek®,
GlaxoSmithKline, Greenford, GB) were added at the indicated
ﬁnal concentrations. To assess T cell proliferation methyl-3[H]-
thymidine (ﬁnal concentration: 0.025 mCi; Perkin Elmer/New
England Nuclear Coorporation, Wellesley, MA)  was added for
the last 18 h prior harvesting of the cells. Methyl-3[H]-thymidine
uptake was measured as described [8].  All T cell prolifer-
ation assays were done in triplicates, means and SD are
shown.
2.3. Cytokine measurement
For cytokine measurement supernatants of T cell activation
assays were collected after 48 h and pooled from triplicate wells.
IFN-, IL-2, IL-10 and IL-13 were measured in the supernatants
using the Luminex System 100 (Luminex, Texas, USA).
2.4. Statistical analyses
The half maximal inhibitory concentrations (IC50) for CsA and
Aza were calculated for each experiment by blotting the percentage
of proliferation (methyl-3[H]-thymidine uptake in the presence of
inhibitor ×100/methyl-3[H]-thymidine uptake without inhibitor)
against the log concentration of the immunosuppressive drug
(mg/ml) using Graph-pad PRISM. Differences between the IC50 val-
ues for CsA and Aza of T cells stimulated in presence of different
costimulatory ligands were calculated using ANOVA for repeated
76 J. Leitner et al. / Immunology Le
Fig. 2. Proliferative response of T cells activated in presence of different costimula-
tory signals. Stimulator cells expressing high levels of membrane-bound anti-CD3
in  conjunction with CD80, CD58, 4-1BBL, ICOS-L, CD54 or no human costimula-
tory molecules were co-cultured with human T cells. 3[H]-thymidine uptake was
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cssessed following 3 days of co-culture (cpm, counts per minute). Circles indicate
utliers. Box plots show the results of 10 independent experiments with T cells from
ifferent healthy donors.
easures. IMB® SPSS statistics software was used for analysis and
eneration of Box plot graphs. Values of p ≤ 0.05 were considered
tatistically signiﬁcant.
. Results
.1. T cell proliferation in the presence of different costimulatory
igands
We  have previously generated a cellular system called T cell
timulator cells that allows for analysing T cells receiving dis-
inct costimulatory signals [5].  This system is based on Bw cells,
 murine thymoma line, that has been engineered to express
embrane-bound anti-CD3 antibody-fragments and can thus gen-
rate “Signal 1” in human T cells by triggering their TCR-complex.
y co-expressing human costimulatory ligands on these stimula-
or cells their contribution to T cell activation processes can readily
e studied. Importantly, with this system we can analyze the net
ffects of individual costimulatory ligands in the absence of other
ccessory molecules that also regulate T cell activation on human
PC.
For this study we have generated and used T cell stimulator
ines expressing CD80, CD58, 4-1BBL, ICOS-L, CD54 and control
timulator cells expressing anti-CD3 antibodies but no costimu-
atory molecules. Those molecules were chosen, because their role
s costimulatory molecules is well described and moreover they
epresent different molecule families. Flow cytometric analysis of
he resulting T cell stimulator lines demonstrate similar amounts
f membrane-bound anti-CD3 and high expression levels of the
espective costimulatory ligands (Fig. 1). In Fig. 2 the proliferative
esponse of T cells stimulated with T cell stimulator lines expressing
he indicated costimulatory molecules or with T cell stimulator cells
xpressing no costimulatory molecule is shown. The costimulatory
olecules tested in these experiments differed in their potencyo induce proliferation. Importantly, all T cell stimulator cells har-
ouring costimulatory ligands induced a stronger proliferation of T
ells than the control T cell stimulator cell line expressing no human
ostimulatory molecules (Fig. 2).tters 140 (2011) 74– 80
3.2. Impact of Cyclosporine A and azathioprine on human T cell
proliferation acting via different costimulatory ligands
We  have previously demonstrated that our system of T cell
stimulator cells is an excellent tool to study the inﬂuence of
immunmodulatory drugs on T cell activation [5,11].In this study
we addressed whether different costimulatory signals can inﬂu-
ence the ability of the immunosuppressive drugs CsA and Aza to
inhibit human T cell proliferation. T cell stimulator cells expressing
high levels of anti-CD3 in conjunction with CD80, CD58, 4-1BBL,
ICOS-L, CD54 as well as T cell stimulator cells expressing no cos-
timulatory molecules were co-cultured with human T cells in the
presence of different concentrations of CsA and Aza. As shown in
Fig. 3A, CsA and Aza led to a dose-dependent inhibition of T cell pro-
liferation. Importantly, the sensitivity of CD28 costimulated T cells
to the anti-proliferative effects of CsA was dramatically reduced.
Furthermore, a strongly impaired immunosuppressive effect of CsA
on CD28 costimulated T cells was also observed when analyzing the
cytokine content of the culture supernatants: CsA concentrations
of 100 ng/ml completely blocked IFN- production in T cells acti-
vated in the absence of CD28 signals, but had little effect on CD28
costimulated T cells (Fig. 3B). Only T cells costimulated via CD28 or
CD2 produced signiﬁcant amounts of IL-10, while IL-4 and IL-2 were
only measured upon CD28 costimulation. CsA was also much less
effective to inhibit the production of these cytokines when T cells
received CD28 signals (supplementary Fig. 1, and data not shown).
We also performed experiments with puriﬁed CD4 and CD8 T
cells from the same donors and found that CD28 costimulation
strongly reduced the anti-proliferative effect of CsA in both sub-
sets (supplementary Fig. 2). In contrast, the T cell-inhibitory effects
of Aza were not modulated by costimulatory signals (Fig. 3A).
3.3. IC50 values of CsA depend on the costimulatory signal
The half maximal inhibitory concentration (IC50) for CsA and Aza
were calculated from dose-inhibition curves for T cells activated in
the presence of T cell stimulator cells expressing the indicated cos-
timulatory ligands. Representative dose-inhibition curves for each
costimulatory molecule are shown in Fig. 4.
Cumulative results of the IC50 values obtained with T cells from
10 healthy donors are shown in Fig. 5. In the case of CsA the
median half maximal inhibitory concentration for T cells stimu-
lated via CD28 compared to T cells receiving no costimulatory signal
was  increased more than 10000-fold (median IC50 values 4 g/ml
versus 0.37 ng/ml; p ≤ 0.05, n = 10). Importantly, our results clearly
demonstrate that decreased sensitivity to the immunosuppressive
effects of CsA is an unique property of CD28 signals, since T cells
stimulated via alternative pathways were inhibited by CsA to the
same extent as T cells receiving no costimulatory signals (Fig. 5A).
To investigate the differential effects of CsA on CD28 signals
and signals generated by alternative costimulators in more detail
we used CD58 expressing stimulator cells, which induced the
highest proliferation and cytokine production in human T cells
besides CD80. We  performed experiments where higher numbers
of CD58 expressing stimulator cells were used to stimulate human T
cells (50,000 instead of 20,000 cells/well). Under these conditions
human T cells proliferated more compared to T cells stimulated
with 20,000 CD80 expressing stimulator cells. However, the use
of higher numbers of CD58-expressing stimulator cells only led
to a slight increase of the IC50 value for CsA. These results clearly
indicate that differences in CsA responsiveness in T cells receiv-
ing CD28 or alternative costimulatory signals are qualitative rather
than quantitative (supplementary Fig. 3).
Furthermore, statistical analysis of our data clearly showed that
CD28 signals are completely ineffective in reducing Aza mediated
T cell suppression and the IC50 values obtained for this drug were
J. Leitner et al. / Immunology L
Fig. 3. The impact of CsA and Aza on the proliferation of human T cells receiving
different costimulatory signals. Human T cells were stimulated with stimulator cells
expressing high levels of anti-CD3 in conjunction with CD80, CD58, 4-1BBL, ICOS-
L,  CD54 or control stimulator cells. On the onset of co-culture (A) Cyclosporine A
(CsA) (upper panel) or Azathioprine (Aza) (lower panel) were added at the indi-
cated ﬁnal concentrations. 3[H]-thymidine uptake was assessed following 3 days
of  co-culture (cpm, counts per minute). (B) The IFN- concentration in the culture
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supernatants was  measured using a Luminex-based assay. Log IC50 values (mg/ml)
re  indicated. Data show ± SD of triplicates from one experiment. The experiment
hown is representative for 10 independently performed.
ot inﬂuenced by any of the costimulatory signals investigated in
his study (Fig. 5B).
. Discussion
CD28 is generally regarded as the primary and most potent
ostimulatory receptor on T cells and consequently many studies
ave investigated how CD28 signals contribute to T cell activation
nd differentiation processes. Several earlier studies have demon-
trated that CD28 triggering greatly reduces the inhibitory effects ofetters 140 (2011) 74– 80 77
CsA on the proliferation and cytokine production of human T cells
[6,7]. However, triggering of numerous alternative receptors can
generate potent costimulatory signals in T cells and animal stud-
ies demonstrate that productive immune responses occur in the
absence of CD28 signals [12,13]. Our study is the ﬁrst to address
whether alternative costimulatory signals can also interfere with
CsA-mediated T cell suppression. Since activated APC express a
plethora of accessory molecules, it is difﬁcult to study the role of dis-
tinct costimulatory pathways in T cells stimulated by natural APC.
We thus relied on a previously described cellular system, which
allows studying human T cells that were activated in presence of
individual costimulatory ligands of choice [5,9,10].
Our results clearly show that decreased sensitivity to the anti-
proliferative effects of CsA is a unique feature of CD28 signals,
since it was not observed with T cells activated by alternative cos-
timulatory pathways. Although CD28 costimulation induced the
strongest proliferative response we  suggest that this is a qualita-
tive effect. In support for this hypothesis we observed that IC50
values obtained for CD2 costimulated T cells, which also had very
strong proliferative responses, were even slightly lower than those
obtained for T cells stimulated via ICOS, which induced much less
T cell proliferation and cytokine production (Figs. 2 and 5 and data
not shown). Furthermore, we  demonstrate that even under condi-
tions where non-CD28 costimulation induced higher proliferative
responses than CD28 costimulation, the dramatic differences in the
IC50 values for CsA are not signiﬁcantly affected (supplementary
Fig. 3). We  have recently shown that Efalizumab, a CD11a anti-
body, acts as a very potent inhibitor of T cell activation and that
presence of CD28 costimulation is able to completely override the
T cell inhibitory effects of this therapeutic antibody. Interestingly
this effect was  also observed with CD2 costimulation whereas ICOS,
LFA-1 or 4-1BB signals were completely ineffective in reverting
Efalizumab effects [11]. This indicates that T cell costimulatory
signals have distinct qualities and thus can have unique abili-
ties to interfere with immunosuppressive and immunomodulatory
drugs.
CsA acts by forming a complex with immunophilin, which
inhibits the Ca2+/calmodulin-dependent serine-threonine phos-
phatase calcineurin. Inactive calcineurin is unable to activate
the nuclear factor of activated T cells (NFAT). Previous work by
Ghosh et al. has demonstrated that NFAT can be activated in a
CsA-resistant pathway that is independent of calcineurin [14].
Furthermore, the authors showed that this pathway is induced
via CD28, which would explain why CsA inhibition of calcineurin
signaling can be overcome by CD28 costimulation. The exact
mechanisms for this phenomenon have not been deﬁned, but
okadaic acid sensitive serine/threonine phosphatases have been
demonstrated to mediate CsA-resistant transactivation of the IL-2
promotor presumably by targeting NFAT [15,16].
Importantly, our data demonstrate that CD28 costimulation
does not result in a general insensitivity to immunosuppressive
agents, since Aza reduced the proliferation of T cells stimulated via
CD28 or alternative costimulatory molecules to a similar extent.
Successful clinical trials established CD28 costimulation block-
ade mediated by the CTLA-4Ig derivative Belatacept as emerging
treatment modality to prevent acute rejection and protect renal
function in kidney transplant recipients [17–19].  The results of
our study suggest synergistic effects during the combined use of
CTLA-4Ig and CsA, which target CD28 and alternative costimulatory
pathways, respectively. In standard immunosuppressive regimen
high doses of CsA might be required to overcome the low effec-
tivity of this drug to block the activation of T cells through the
CD28 pathway. Since very low concentrations of CsA are sufﬁ-
cient to inhibit T cells that do not receive CD28 signals, upon CD28
blockade the adverse effects of CsA could be largely avoided by
administering this drug at greatly reduced doses. Current treat-
78 J. Leitner et al. / Immunology Letters 140 (2011) 74– 80
Fig. 4. Dose inhibition curves for CsA (A) or Aza (B) for T cells stimulated in the presence of different costimulatory ligands and for T cells activated in absence of costimulatory
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xperiments.
ent regimen-in renal graft recipients aim to achieve CsA-plasma
evels of 40–250 ng/ml. Based on the results of our in vitro experi-
ents these concentrations are 100 times higher than the median
C50 values determined for human T cells activated in the absence
f CD28 costimulation, which ranged from 0.6 ng/ml to 0.2 ng/ml.
oreover, these concentrations are clearly insufﬁcient to inhibit Tells that receive strong costimulation via CD28 as their IC50 value
as found to be in the g-range (Fig. 5A). Importantly, such syner-
istic effects cannot be expected when CTLA-4Ig is combined with
za and possibly other immunosuppressive agents, which halt thee indicated. Each curve shown is representative for ten independently performed
proliferation of T cells regardless of the costimulatory signals they
receive.
In some experimental transplant models the administration of
CTLA-4Ig was suggested to induce tolerance and promoted long
term survival [20,21]. There are studies that found concomitant use
of CsA to be detrimental to tolerance induction since it prevented
activation-induced cell death (AICD) of effector T cells [22–25].
However, in these studies high concentrations of CsA were used.
Moreover, other studies have not observed impairment of long-
term graft survival by combined treatment with CTLA-4Ig and CsA
J. Leitner et al. / Immunology L
Fig. 5. IC50 values for T cell proliferation in the presence of different costimula-
tory signals. The cumulative results of the IC50 values for (A) CsA or (B) Aza treated
human T cells activated in the presence of different costimulatory ligands. Circles
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[ndicate outliers. Box plots represent data from ten experiments independently per-
ormed. Asterisks indicate signiﬁcant differences (p ≤ 0.05, n = 10). Median values are
ndicated.
26] and additive effects of CTLA-4Ig and CsA were also described
27,28].
In non-human primate models CTLA-4Ig has not been shown to
nduce indeﬁnite graft survival or tolerance [29,30], which might
e due to an important role of CD28 independent T cell activation
athways. In human or primate T cells, the CD58-CD2 interaction
unctions as a second major T cell activation axis that is much
ore potent than other non-CD28 costimulators [2,5,31–33].  This
athway is not operative in murine T cells, since mice lack CD58.
urthermore, following chronic stimulation human but not murine
D8+ T cells loose CD28 expression and thus become dependent
n alternative costimulatory pathways for activation [34]. There-
ore, in humans and primates alternative costimulatory pathways
re likely to have more important contributions to T cell activa-
ion processes than in rodents and consequently the efﬁcacy of
mmunosuppressive drugs in blocking human T cells activated by
uch signals is of high interest.
. ConclusionThe efﬁcacy of immunosuppressive drugs in blocking human
 cells, activated by different costimulatory signals, is of high
nterest especially under conditions where standard immunosup-
ressive drugs are co-administered with agents that speciﬁcally
[
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block selected costimulatory pathways. The interplay between cos-
timulatory molecules and immunosuppressive agents should be
considered when combining these drugs with costimulation block-
ers.
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